Imugene (ASX:IMU) said data from its azer-cel Phase 1b abstract, published on the American Society of Clinical Oncology (ASCO) website, showed an overall response rate (ORR) of 81% among 16 evaluable patients, according to a Friday Australian bourse filing.
The company said Azer-cel, an off-the-shelf allogeneic CAR T cell therapy targeting CD19 to treat blood cancers, showed responses across multiple lymphoma and leukemia subtypes, including a 60% response rate in diffuse large B-cell lymphoma (DLBCL) and a 100% response rate in marginal zone lymphoma (MZL).
The company's shares rose 22% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments